Biosimilars
Page 2 • 5 itemsTrack global biosimilar approvals, market entry strategies, and regulatory pathways. Gain critical intelligence for your pharmaceutical BD and investment decisions.
Cigna Healthcare Adds Accord BioPharma's IMULDOSA Biosimilar to Preferred Coverage Plans
Cigna Healthcare now covers IMULDOSA (ustekinumab-srlf), Accord BioPharma's biosimilar to STELARA, under commercial plans effective April 15, 2026.
EU Pharmaceutical Legislation Reform: Impact on Generic and Biosimilar Markets 2026-27
The upcoming EU Pharmaceutical Legislation Reform will significantly reshape the landscape for generic and biosimilar drugs, influencing market dynamics through 2026-27.
EMA Biosimilar Policy: Market Impact and Regulatory Insights 2024
This article delves into the EMA's 2024 biosimilar policy, analyzing its market impact and regulatory insights for biologics such as adalimumab.
EMA Decision on Biosimilar Pricing: Key Insights for Oncology Market
The EMA's recent decision on biosimilar pricing offers crucial insights for the oncology market, influencing drug accessibility and treatment options.
Denosumab Biosimilar Authorization by EMA: Key Details
The EMA has authorized Denosumab biosimilars, marking a significant advancement in osteoporosis treatment and improving patient access to effective therapies.